Latest Market Share News

EV Resources has begun refurbishing its Tecomatlán Processing Plant in Mexico, marking a pivotal shift from exploration to near-term antimony production amid tightening global supply. The company aims to leverage this low-cost, staged approach to secure a first mover advantage in the critical minerals market.

Challenger Limited’s attempt to acquire Pepper Money has been declined by Pepper’s board, while Challenger moves forward with a $150 million share buy-back program.

Clover Corporation has reported a robust first half for FY26, with revenue climbing 17% and margins expanding significantly, underpinning a confident revenue forecast for the full year.

Findi Limited has secured $9 million in the first tranche of its $25 million placement, enabling debt reduction and strategic shifts including the cancellation of the Nova transaction and increased ownership in Transaction Solutions International.

Turners Automotive Group has raised its net profit guidance for FY26 to $63 million, driven by robust vehicle sales and record finance lending, despite a goodwill write-down in its EC Credit division.

EVE Health Group has increased its placement funding to $1.3 million, backed by a cornerstone investor with pharmaceutical expertise, advancing its reformulated drug programs targeting billion-dollar global markets.

Reliance Worldwide Corporation has announced an additional A$120 million on-market share buy-back, reinforcing its confidence in the company’s strategy and financial health.

Shriro Holdings Limited has announced a $15 million off-market share buy-back at $0.81 per share, representing nearly 26% of its issued capital. The move aims to return excess capital to shareholders while supporting the company’s capital-light growth model.

Osteopore Limited has secured non-exclusive distribution rights for an injectable regenerative bone filler across Southeast Asia, marking a strategic expansion of its orthopaedic product portfolio and opening new revenue channels.

Tetratherix Limited has raised approximately $5 million to fast-track its Tutelix prostate spacer into pivotal clinical trials across Australia and the US, aiming to improve radiation therapy for prostate cancer patients.

Orica reports solid first-half earnings growth led by digital and specialty chemicals, while launching a $100 million cost reduction program to navigate supply disruptions and litigation headwinds.

Sports Entertainment Group Limited has announced a significant on-market share buy-back program, aiming to repurchase up to 10% of its shares over the next year starting March 2026. The move reflects the board's confidence in the company's underlying value amid current market pricing.